BTG International announced that Voraxaze (glucarpidase injection) is now available to treat patients with toxic levels of methotrexate (>1μmol/L) in their blood due to kidney failure.

Patients receiving high dose methotrexate chemotherapy may develop kidney failure, reducing their ability to clear methotrexate from the body. Voraxaze is an enzyme that rapidly reduces methotrexate levels by breaking it down to a form that can be eliminated from the body. Voraxaze is to be administered as a single intravenous injection of 50U/kg.

Voraxaze injection is available from BTG international as a lyophilized powder containing 1,000 units per vial.

For more information call (855) 786-7292 or visit www.btgplc.com.